Advanced search
1 file | 1.00 MB Add to list

M2-based influenza vaccines : recent advances and clinical potential

Annasaheb Kolpe (UGent) , Bert Schepens (UGent) , Walter Fiers and Xavier Saelens (UGent)
(2017) EXPERT REVIEW OF VACCINES. 16(2). p.123-136
Author
Organization
Abstract
Introduction: Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.Areas covered: Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines. Expert commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.
Keywords
Clinical trial, influenza A virus, M2e, matrix protein 2, broadly protective vaccines, broadly protecting antibodies, VIRUS-LIKE PARTICLES, IMPROVED CROSS-PROTECTION, DEPENDENT CELLULAR CYTOTOXICITY, M2 EXTRACELLULAR DOMAINS, A-VIRUS, MATRIX PROTEIN-2, MONOCLONAL-ANTIBODY, FUSION PROTEIN, IMMUNE-RESPONSES, UNIVERSAL VACCINE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • binary/octet-stream
    • |
    • 1.00 MB

Citation

Please use this url to cite or link to this publication:

MLA
Kolpe, Annasaheb et al. “M2-based Influenza Vaccines : Recent Advances and Clinical Potential.” EXPERT REVIEW OF VACCINES 16.2 (2017): 123–136. Print.
APA
Kolpe, A., Schepens, B., Fiers, W., & Saelens, X. (2017). M2-based influenza vaccines : recent advances and clinical potential. EXPERT REVIEW OF VACCINES, 16(2), 123–136.
Chicago author-date
Kolpe, Annasaheb, Bert Schepens, Walter Fiers, and Xavier Saelens. 2017. “M2-based Influenza Vaccines : Recent Advances and Clinical Potential.” Expert Review of Vaccines 16 (2): 123–136.
Chicago author-date (all authors)
Kolpe, Annasaheb, Bert Schepens, Walter Fiers, and Xavier Saelens. 2017. “M2-based Influenza Vaccines : Recent Advances and Clinical Potential.” Expert Review of Vaccines 16 (2): 123–136.
Vancouver
1.
Kolpe A, Schepens B, Fiers W, Saelens X. M2-based influenza vaccines : recent advances and clinical potential. EXPERT REVIEW OF VACCINES. 2017;16(2):123–36.
IEEE
[1]
A. Kolpe, B. Schepens, W. Fiers, and X. Saelens, “M2-based influenza vaccines : recent advances and clinical potential,” EXPERT REVIEW OF VACCINES, vol. 16, no. 2, pp. 123–136, 2017.
@article{8512291,
  abstract     = {Introduction: Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.Areas covered: Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines.
Expert commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.},
  author       = {Kolpe, Annasaheb and Schepens, Bert and Fiers, Walter and Saelens, Xavier},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keywords     = {Clinical trial,influenza A virus,M2e,matrix protein 2,broadly protective vaccines,broadly protecting antibodies,VIRUS-LIKE PARTICLES,IMPROVED CROSS-PROTECTION,DEPENDENT CELLULAR CYTOTOXICITY,M2 EXTRACELLULAR DOMAINS,A-VIRUS,MATRIX PROTEIN-2,MONOCLONAL-ANTIBODY,FUSION PROTEIN,IMMUNE-RESPONSES,UNIVERSAL VACCINE},
  language     = {eng},
  number       = {2},
  pages        = {123--136},
  title        = {M2-based influenza vaccines : recent advances and clinical potential},
  url          = {http://dx.doi.org/10.1080/14760584.2017.1240041},
  volume       = {16},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: